Replies to post #6 on Amylin Pharmaceuticals Inc. (AMLN)

[SeriousMoney]

Drug Stocks Up After Choppy Week
Peter Kang, Forbes.com, 10.31.05, 7:00 AM ET

Amylin Pharmaceuticals (nasdaq: AMLN - news - people ) pulled back from new all-time highs last week, after the specialty drugmaker announced third-quarter results last Wednesday. The company reported a loss of 65 cents per share on revenue of $25.9 million, compared with a consensus estimate for a loss of 57 cents per share on revenue of $30.7 million. Morgan Stanley raised the price target on the stock to $39 from $29 and has high hopes for Amylin's exenatide LAR, an experimental diabetes treatment analyst Steven Harr says has "mega-blockbuster potential." Harr expects "strongly positive" midstage trial results for exenatide LAR used in combination with a relatively new class of drugs known as peroxisome proliferator-activated receptors (PPARs). The stock closed Friday down 7% for the week, but shares have gained 43% year-to-date.

http://www.forbes.com/markets/2005/10/28/merck-pfizer-earnings-cx_pk_1028roundupbiotech.html?partner...